InvestorsHub Logo
Followers 4
Posts 171
Boards Moderated 0
Alias Born 03/02/2015

Re: None

Tuesday, 06/08/2021 9:11:33 AM

Tuesday, June 08, 2021 9:11:33 AM

Post# of 917
OTLK - Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3

Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial June 8, 2021
Topline readout of data from NORSE TWO (Phase 3-FDA) targeted for calendar Q3 2021
New Biologics License Application (BLA) filing anticipated in calendar Q1 2022
https://ir.outlooktherapeutics.com/node/9516/pdf

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OTLK News